GLP-1
Typical Dosing Protocols (Research/Compounded Use Only) – Semaglutide
Common protocol: Start with 0.25 mg subcutaneously once weekly for the first 4 weeks (titration phase). Increase every 4 weeks as tolerated:
Weeks 5–8: 0.5 mg weekly
Weeks 9–12: 1 mg weekly
Weeks 13–16: 1.7 mg weekly
Maintenance: 2.4 mg once weekly
Other reported ranges:
Milder goals / better tolerance: 0.5–1 mg weekly
Aggressive fat loss: Up to 2.4 mg weekly (standard maintenance dose)
Microdosing: Some start as low as 0.1–0.25 mg with slower titration
Reconstitution example (for research vials, common 5 mg or 10 mg): Add 2 mL bacteriostatic water.
0.25 mg = 0.05 mL (5 units on U-100) at 5 mg/mL concentration
1 mg = 0.2 mL (20 units) at 5 mg/mL concentration
2.4 mg = 0.48 mL (48 units) at 5 mg/mL concentration
Administration: Subcutaneous injection (abdomen, thigh, or upper arm) on the same day each week, with or without food.
Dosing is highly individualized based on goals (weight loss, appetite control, metabolic support), tolerance, and response—consult a qualified healthcare provider experienced with GLP-1 therapies for personalized guidance and monitoring. This is for informational purposes only.
Key Potential Benefits of Semaglutide
Powerful Appetite Suppression and Satiety Enhancement
Mimics the natural GLP-1 hormone, activating receptors in the brain (hypothalamus and brainstem) to strongly increase feelings of fullness and reduce hunger signals.
Decreases overall food cravings, emotional eating, and caloric intake by improving control over eating behaviors and prospective food consumption.
Promotes sustained satiety that lasts throughout the day, making calorie restriction more manageable without constant willpower.
Significant Weight Loss and Fat Reduction
Delivers robust, dose-dependent body weight reduction (often 10–15% or more over 68–104 weeks in clinical studies) when combined with diet and exercise.
Preferentially targets visceral and abdominal fat while supporting overall fat mass loss through reduced energy intake and enhanced metabolic efficiency.
Contributes to meaningful improvements in body composition for long-term weight management.
Improved Glycemic Control and Metabolic Health
Enhances glucose-dependent insulin secretion from the pancreas while suppressing inappropriate glucagon release, leading to better blood sugar regulation.
Slows gastric emptying to stabilize post-meal glucose spikes and improve insulin sensitivity.
Supports favorable changes in lipid profiles, blood pressure, and inflammatory markers for broader cardiometabolic benefits.
Cardiovascular and Organ Protection
Reduces the risk of major adverse cardiovascular events (e.g., heart attack, stroke) in individuals with obesity or type 2 diabetes.
Provides protective effects on the heart, kidneys, and other organs through improved metabolic signaling and reduced systemic stress.
May offer additional neuroprotective potential, with emerging research on benefits for brain health and conditions like Alzheimer’s.
Support for Lean Mass Preservation and Energy Balance
Helps maintain or proportionally preserve lean muscle mass relative to total weight loss when paired with adequate protein intake and resistance training.
Improves energy expenditure efficiency and metabolic rate adaptations during weight reduction.
Enhances overall physical functioning, stamina, and quality of life through better body composition and metabolic health.
Broader Wellness and Long-Term Resilience
Promotes sustainable lifestyle changes by reducing hunger-driven barriers to healthy eating and activity.
Supports improved mood, reduced inflammation, and greater physiological resilience in aging or metabolically stressed individuals.
Contributes to comprehensive health improvements, including better sleep patterns and daily vitality as part of weight and metabolic optimization.
Semaglutide is a long-acting GLP-1 receptor agonist with a well-established track record in clinical research for both glycemic control and chronic weight management.
